Alpharadin, a novel, highly targeted alpha pharmaceutical with a good safety profile for patients with CRPC and bone metastases: Combined safety analyses of phase I and II clinical trials

• The overall adverse event profile was consistent with that expected for patients undergoing treatment for advanced cancer with bone metastases, and was characterized by gastrointestinal events (nausea, vomiting, diarrhea, constipation), bone pain, fatigue and anaemia. No signs of renal or hepatic toxicity were seen. • Serious adverse events were reported in 34% of patients (98/292). Those recorded in more than 2% of the patients were bone pain (5%), anaemia (4%), spinal cord compression (3%) and disease progression (2.7%). • In the placebo arm of the BC1-02 study, bone pain was the only serious adverse event reported in more than one patient (3 patients/10%). Amongst other events, anaemia and spinal cord compression was reported by 1 patient (3%).